Publisher
Springer Nature Switzerland
Reference25 articles.
1. Adler L IV, Boyer NP, Chen C, Ablonczy Z, Crouch RK, Koutalos Y. The 11-cis retinal origins of lipofuscin in the retina. Prog Mol Biol Transl Sci. 2015;134:e1–12. https://doi.org/10.1016/bs.pmbts.2015.07.022. ISBN 9780128010594. PMID 26310175.
2. Audo I, Weleber R, Stout T, Lauer AK, Pennesi ME, Mohand-Said S, Barale P-O, Buggage R, Wilson DJ, Sahel JA. Early findings in a phase I/IIa clinical program for Stargardt disease. Investig Ophthalmol Vis Sci. 2015;56:3819.
3. Campa C, Gallenga CE, Bolletta E, Perri P. The role of gene therapy in the treatment of retinal diseases: A review. Curr Gene Ther. 2017;17:194–213.
4. Cideciyan AV, Swider M, Aleman TS, Tsybovsky Y, Schwartz SB, Windsor EA, et al. ABCA4 disease progression and a proposed strategy for gene therapy. Hum Mol Genet. 2009;18(5):931–41. https://doi.org/10.1093/hmg/ddn421. PMC 2640207. PMID 19074458.
5. Dalkara D, Goureau O, Marazova K, Sahel JA. Let there be light: gene and cell therapy for blindness. Hum Gene Ther. 2016;27:134–47.